Enner S, Baillie J, DeWitt J, Vege SS. American college of > 자유게시판

Enner S, Baillie J, DeWitt J, Vege SS. American college of gastroenterol ogy guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(1400?415):1416. 49. Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, Dunn JA, Dervenis C, Lacaine F, Hickey H, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol. 2003;14:675?2. 50. Apps MG, Choi EH, Wheate NJ. The stateofplay and future of platinum drugs. Endocr Relat Cancer. 2015;22:R219?3. 51. Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies Staurosporine for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015;6:185?00. 52. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancre atic cancer. Cancer Treat Rev. 2012;38:843?3. 53. Mizutani Y, Sato N, Kawauchi A, Nonomura N, Fukushima M, Miki T. Cisplatininduced in vivo differentiation of human embryonal carcinoma. BJU Int. 2002;89:454?. 54. Prabhakaran P, Hassiotou F, Blancafort P, Filgueira L. Cisplatin induces dif ferentiation of breast cancer cells. Front Oncol. 2013;3:134. 55. Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanch bury JS, Krivak TC. BRCA1/2 mutations and expression: response to plati num chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012;125:677?2. 56. Turner NC, Tutt AN. Platinum chemotherapy for BRCA1related breast cancer: do we need more evidence? Breast Cancer Res. 2012;14:115. 57. Wiedemeyer WR, Beach JA, Karlan BY. Reversing platinum resistance in highgrade serous ovarian carcinoma: targeting BRCA and the homolo gous recombination system. Front Oncol. 2014;4:34. 58. Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, PaluchShimon S, Kaufman B, GershoniBaruch R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111:1132?. 59. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM. Truncated BRCA2 is cytoplasmic: implications for cancerlinked mutations. Proc Natl Acad Sci U S A. 1999;96:13920?. 60. Watson P, Lieberman R, Snyder C, Clark VJ, Lynch HT, Holt JT. Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers. J Clin Oncol. 2009;27:3894?00. 61. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovar ian cancer risk. J Clin Oncol. 1998;16:2417?5. 62. Montagna M, Agata S, De Nicolo A, Menin C, Sordi G, ChiecoBianchi L, D'Andrea E. Identification of BRCA1 and BRCA2 carriers by allelespecific gene expression (AGE) analysis. Int J Cancer. 2002;98:732?. 63. Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, Tung N, Horsman D, Isaacs C, Monteiro AN, et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer. 2004;3:1?0. 64. Ploquin A, Baldini C, Vuagnat P, Makhloufi S, Desauw C, Hebbar M. Pro longed survival in a patient with a pancreatic acinar cell carcinoma. Case Rep Oncol. 2015;8:447?0.Submit your next manuscript to BioMed Central and we will help you at every step:?We accept pre-submission inquiries ?Our selector tool helps you to find the most relevant journal ?We provide round the clock customer support PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/7500280 ?Convenient online submission ?Thorough peer review ?Inclusion in PubMed and all major in.